A Pharmacologic Approach to the Use of Glyburide in Pregnancy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Despite widespread use of glyburide to treat pregnancy-related hyperglycemia, the dosing regimen is based in large part on pharmacokinetic and pharmacodynamic studies in men and nonpregnant women. Like many medications used by pregnant women, adequate pharmacokinetic and pharmacodynamic data in pregnancy have been sorely lacking. This lack of information can lead to both overdosing with excessive side effects and underdosing with an inadequate therapeutic response. Both of these problems may apply to glyburide use in pregnancy. This commentary provides a pharmacologic basis for altering the glyburide administration regimen. Taking glyburide 1 hour before a meal may improve efficacy in patients with pregnancy-related hyperglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although glyburide was previously thought not to cross the placenta in significant amounts,61 more recent studies using more sensitive assays have demonstrated significant and highly variable transplacental transfer of glyburide.62,63”
From Gestational Diabetes Mellitus (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Women should be informed that oral agents cross the placenta”
From Gestational Diabetes Mellitus (2019) · cites this paper as [63]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 2×
“These findings differ from those previously published.(10) These differences, however, can be attributed to assay methodology.”
BackgroundResultThe Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308 · cited 2×
“Collectively, these studies have demonstrated that in nonpregnant women, glyburide peaks 4 hours after ingestion and plasma concentrations decrease over the ensuing 8 hours and the drug is still detectable 24 hours after ingestion.(2,3) Glyburide sensitizes the pancreas to enhance insulin secretion particularly after…”
BackgroundHebert, M., Ma, X., Naraharisetti, S., Krudys, K., Umans, J., Hankins, G., Caritis, S., Miodovnik, M., Mattison, D., Unadkat, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.5 · Cited by 252
Self-citationHypoglycemic Activity of Glyburide (Glibenclamide) Metabolites in Humans
Rydberg, T., Jönsson, A., Røder, M., & Melander, A. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.1026 · Cited by 112 · cited 1×
“In addition, in humans, two of the metabolites of glyburide exhibit glucose-lowering activity, which appears to be insulin-mediated.(7) There is also evidence that the response to glyburide in nonpregnant patients does not increase at concentrations above 10 mg daily.”
BackgroundSartor, G., Melander, A., Scherst�n, B., & W�hlin-Boll, E. (1980) · Diabetologia · doi:10.1007/bf01228296 · Cited by 93 · cited 1×
“Glyburide sensitizes the pancreas to enhance insulin secretion particularly after a meal or a glucose load.(4,5) The insulin response to meals or From the Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and the Department of Pharmac…”
BackgroundOral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety
Nicholson, W., & Baptiste-Roberts, K. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2010.10.018 · Cited by 72 · cited 1×
“meal.(10,11) This dosing regimen may contribute to hypoglycemia or, conversely, to a perceived lack of glucose control.”
BackgroundPharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics
Groop, L., W�hlin-Boll, E., Groop, P., T�tterman, K. J., Melander, A., Tolppanen, E. ‐., & Fyhrqvist, F. (1985) · European Journal of Clinical Pharmacology · doi:10.1007/bf00607919 · Cited by 63 · cited 3×
“This would likely improve efficacy by optimizing the insulin response to a meal because insulin secretion with a meal or glucose elevations is proportional to the glyburide concentration.(4,8) Second, because glyburide concentrations return to baseline within 8–10 hours of ingestion with daytime dosing (Fig.”
BackgroundImproved effect of glibenclamide on administration before breakfast
Sartor, G., Lundquist, I., Melander, A., Scherst�n, B., & W�hlin-Boll, E. (1982) · European Journal of Clinical Pharmacology · doi:10.1007/bf00542327 · Cited by 43 · cited 4×
“This would likely improve efficacy by optimizing the insulin response to a meal because insulin secretion with a meal or glucose elevations is proportional to the glyburide concentration.(4,8) Second, because glyburide concentrations return to baseline within 8–10 hours of ingestion with daytime dosing (Fig.”
BackgroundInfluentialIs There a Concentration-Effect Relationship for Sulphonylureas?
Melander, A., Donnelly, R., & Rydberg, T. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834030-00001 · Cited by 26
Go, E. H., Kyriakidou-Himonas, M., & Berelowitz, M. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.443 · Cited by 10 · cited 2×
“In patients with type 2 diabetes mellitus receiving glyburide orally without a meal, insulin secretion is not increased nor is fasting insulin concentration.(4,6) Glucose concentrations decrease with glyburide administration even in the fasting state suggesting that at least some of the glucose-lowering effect of glyb…”
Background
Cited by
Szmuilowicz, E. D., Josefson, J. L., & Metzger, B. E. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.05.001 · Cited by 364
Chakera, A. J., Steele, A. M., Gloyn, A. L., Shepherd, M. H., Shields, B., Ellard, S., & Hattersley, A. T. (2015) · Diabetes Care · doi:10.2337/dc14-2769 · Cited by 289
“nancy (see above) and recent evidence that glibenclamide crosses the placenta (87,88) and result in increased fetal growth and macrosomia (89).”
BackgroundGestational Diabetes: Overview with Emphasis on Medical Management
Lende, M., & Rijhsinghani, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17249573 · Cited by 240
“This may lead to increasing the glyburide dose but with a negative subsequent effect of hypoglycemia since the peak activity is 2–3 h following a meal [40].”
BackgroundA cautionary response to SMFM statement: pharmacological treatment of gestational diabetes
Barbour, L. A., Scifres, C., Valent, A. M., Friedman, J. E., Buchanan, T. A., Coustan, D., Aagaard, K., Thornburg, K. L., Catalano, P. M., Galan, H. L., et al. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.06.013 · Cited by 101
Drug development research in pregnant and lactating women
Ren, Z., Bremer, A. A., & Pawlyk, A. C. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.04.227 · Cited by 105
Wexler, D. J., Powe, C. E., Barbour, L. A., Buchanan, T., Coustan, D. R., Corcoy, R., Damm, P., Dunne, F., Feig, D. S., Ferrara, A., et al. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002726 · Cited by 80
Gestational diabetes mellitus management with oral hypoglycemic agents
Ryu, R. J., Hays, K. E., & Hebert, M. F. (2014) · Seminars in Perinatology · doi:10.1053/j.semperi.2014.08.012 · Cited by 59
Zhao, Y., Hébert, M. F., & Venkataramanan, R. (2014) · Seminars in Perinatology · doi:10.1053/j.semperi.2014.08.011 · Cited by 58
Pregnancy outcomes in women with an early diagnosis of gestational diabetes mellitus
Feghali, M. N., Abebe, K. Z., Comer, D. M., Caritis, S., Catov, J. M., & Scifres, C. M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.004 · Cited by 50
Self-citationMetformin for gestational diabetes mellitus: progeny, perspective, and a personalized approach
Barbour, L. A., & Feig, D. S. (2019) · Diabetes Care · doi:10.2337/dci18-0055 · Cited by 44
“, and the concentrations of metformin and glyburide in pregnant women are ;80% and ;50%, respectively, of those in nonpregnant women due to increased clearance (28,29).”
BackgroundOral Antihyperglycemic Treatment Options for Type 2 Diabetes Mellitus
Brietzke, S. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.012 · Cited by 49
“Glyburide, glipizide, and glimepiride are all rated as class C in pregnancy, and glyburide has been studied and established as noninferior to insulin therapy in gestational diabetes, with no evidence of adverse fetal or maternal outcomes.(38,39) The cardiovascular safety question that has dogged the SU class remains u…”
BackgroundOral Agents for the Treatment of Gestational Diabetes
Finneran, M. M., & Landon, M. B. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1093-2 · Cited by 36
Pharmacological Management of Gestational Diabetes Mellitus
Mukerji, G., & Feig, D. S. (2017) · Drugs · doi:10.1007/s40265-017-0807-0 · Cited by 41
“Glyburide is more effective for post-prandial hyperglycemia than for fasting hyperglycemia [71].”
BackgroundTreating diabetes during pregnancy
Klein, J., Charach, R., & Sheiner, E. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.988140 · Cited by 27
“Interestingly the oral clearance rate of glyburide is doubled in pregnant women compared to non-pregnant women, but the current dosing recommendation does not take this into consideration as the values are based on pharmocokinetic studies performed in men and non-pregnant women [56].”
BackgroundPharmacological treatment of gestational diabetes mellitus: point/counterpoint
Langer, O. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.01.024 · Cited by 27
Venkatesh, K. K., Chiang, C., Castillo, W. C., Battarbee, A., Donneyong, M. M., Harper, L. M., Costantine, M. M., Saade, G. A., Werner, E., Boggess, K., et al. (2021) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16960 · Cited by 29
Reynolds, R. M., Denison, F. C., Juszczak, E., Bell, J. L., Penneycard, J. M., Strachan, M. W. J., Lindsay, R. S., Alexander, C. I., Love, C. D. B., Whyte, S., et al. (2017) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-017-1505-3 · Cited by 23
“Metformin crosses the placenta, but there is debate about whether this is true for glibenclamide [26, 27].”
BackgroundPharmacotherapy for gestational diabetes
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Papanas, N. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1509955 · Cited by 19
“Transplacental transporters are often not specific to one agent [75].”
BackgroundPharmacologic Treatment of Diabetes in Pregnancy
Bishop, K. C., Harris, B. S., Boyd, B. K., Reiff, E. S., Brown, L., & Kuller, J. A. (2019) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000671 · Cited by 21
“However, giving a daily dose greater than 20 mg may increase the risk of hypoglycemic events as well as neonatal hypoglycemia and is therefore not recommended.(26)”
BackgroundIs Glyburide Safe in Pregnancy?
Kimber-Trojnar, Ż., Marciniak, B., Patro-Małysza, J., Skórzyńska-Dziduszko, K., Poniedziałek‐Czajkowska, E., Mierzyński, R., Gałczyński, K., Trojnar, M. P., Leszczyńska‐Gorzelak, B., & Oleszczuk, J. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140330200254 · Cited by 20
“This pharmacokinetic and metabolic profile indicates that the presently recommended glyburide administration regimen may not be most favourable for pregnant patients [44].”
BackgroundInfluentialGestational diabetes mellitus and COVID-19: The epidemic during the pandemic
Mendez, Y. H., Radilla, L. A., Chabolla, L. D., Cruz, A. C., Luna, J., & Surani, S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i8.1178 · Cited by 18
Novel therapies for diabetes mellitus in pregnancy
Feghali, M. N., & Scifres, C. (2018) · BMJ · doi:10.1136/bmj.k2034 · Cited by 17
Nunes, P. R., Bueno-Pereira, T. O., Bertozzi-Matheus, M., Grandini, N. A., Siqueira, J. S., Corrêa, C. R., Abbade, J. F., & Sandrim, V. C. (2022) · Antioxidants · doi:10.3390/antiox11081620 · Cited by 12
“showed new dosages for women with GDM, but additional research is required to determine whether higher dosages can or should be used because GB crosses the placenta, and this should be taken into consideration for the pros and cons when considering the use of new drugs for pregnancy-related disorders [38].”
BackgroundOptimizing drug therapy during pregnancy: a spotlight on population pharmacokinetic modeling
Dodeja, P., Chaphekar, N., Caritis, S. N., & Venkataramanan, R. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2420195 · Cited by 11
“An example of this is illustrated by the adjustment of the glyburide dose in pregnant women [12].”
Self-citationThe Use of Non-insulin Agents in Gestational Diabetes: Clinical Considerations in Tailoring Therapy
Blair, R. A., Rosenberg, E. A., & Palermo, N. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1243-1 · Cited by 10
Insulin vs Glyburide for Gestational Diabetes
Coustan, D. R., & Barbour, L. A. (2018) · JAMA · doi:10.1001/jama.2018.4561 · Cited by 9
Mehta, D., Li, M., Nakamura, N., Chidambaram, M., He, X., Bryant, M., Patton, R. E., Davis, K., & Fisher, J. W. (2022) · Reproductive Toxicology · doi:10.1016/j.reprotox.2022.06.007 · Cited by 7
Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Παπάνας, Ν. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.60 · Cited by 6
“SUs are more effective for post-prandial hyperglycaemia and their plasma concentrations are approximately 50% lower in pregnant women than in non-pregnant patients (15).”
BackgroundMedications for Managing Preexisting and Gestational Diabetes in Pregnancy
Rickert, M. C., Caughey, A. B., & Valent, A. M. (2023) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2022.10.007 · Cited by 5
Examining the Starting Dose of Glyburide in Gestational Diabetes
Tita, A., Biggio, J., Harper, L. M., & Glover, A. V. (2015) · American Journal of Perinatology · doi:10.1055/s-0035-1564063 · Cited by 4
Pharmacological therapy in gestational diabetes – a comparison between insulin and oral therapy
Shmuel, E., Krispin, E., Toledano, Y., Chen, R., Wiznitzer, A., & Hadar, E. (2021) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2021.1875208 · Cited by 7
“A further explanation for this phenomenon and the higher rate of fetal hyperinsulinemia and its possible consequences is found in the recent hypothesis that the use of glyburide does not correspond to its pharmacokinetics [39].”
BackgroundWhich oral hypoglycaemic for gestational diabetes?
Sacks, D. A. (2015) · BMJ · doi:10.1136/bmj.h177 · Cited by 3
Bhamidipaty‐Pelosi, S., Muralidharan, S., Yeley, B., Haas, D. M., & Quinney, S. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082793 · Cited by 4
Hepatic Elimination of Drugs in Gestational Diabetes
González, C. D., Alvariñas, J., Bolaños, R., & Girolamo, G. D. (2018) · Current Clinical Pharmacology · doi:10.2174/1574884713666180326104613 · Cited by 1
Glyburide vs Insulin for Gestational Diabetes—Reply
Sénat, M., Affres, H., & Bouyer, J. (2018) · JAMA · doi:10.1001/jama.2018.10090 · Cited by 1
Uso de hipoglicemiantes orais em pacientes com Diabetes Mellitus gestacional
Tanure, L. M., Alves, S. D. S., Leite, H. V., Cabral, A. C. V., & Brandão, A. H. F. (2014)
Decision making in hyperglycaemia seen in pregnancy
Nagandla, K. (2014) · International e-Journal of Science Medicine & Education · doi:10.56026/imu.8.1.8
“The fact that peak in glucose occurs at 90 minutes after taking a meal suggests that glyburide should be administered at least 60 minutes prior to a meal to prevent postprandial glucose excursions.(42,43) The questions that remain elusive are whether glyburide affects the long term wellbeing of the newborn and the fut…”
BackgroundLandon, M. B. (2026) · Seminars in Perinatology · doi:10.1016/j.semperi.2026.152218
Bouchghoul, H. (2021) · theses.fr (ABES) · doi:10.70675/148e6519z0c6dz4cbfza432z81cde39ecdbc
Safety of Glyburide Use During Pregnancy: A Real-World Study Based on the FAERS Database
Yan, X., Xiang, H., Ou, J., Pan, L., Wang, X., Liu, L., Zhou, Y., Li, Y., Zhang, R., & Wu, Y. (2026) · Hospital Pharmacy · doi:10.1177/00185787261433433
Suresh, A., Jayaprakasan, J., Venkatesan, R., Soujanya, C., & Selvaraj, D. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.107117
Metadata
- Authors
- Caritis, S. N., & Hebert, M. F.
- Affiliations
- University of Pittsburgh (US)
- ORCID
- Caritis, Steve N.
- Venue
- Obstetrics & Gynecology
- Published
- 2013-06
- Volume
- 121
- Issue
- 6
- Pages
- 1309-1312
- ISSN
- 0029-7844 (ISSN-L)
- PMC
- PMC5738659
- OpenAlex
- W1985061571
- Cited by
- 41
- References
- 10
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 4 · 2018: 11 · 2017: 2 · 2015: 3 · 2014: 7
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD047892, U54HD047905, U10HD047892, HD047905, U10HD047905)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glibenclamide, pregnancy, gestational diabetes mellitus, hyperglycemia, pharmacokinetics, pharmacodynamics, dosing regimen, timing of drug administration, sulfonylureas, drug safety in pregnancy
- MeSH terms
- Administration, Oral, Blood Glucose, C-Peptide, Female, Glyburide, Humans, Hypoglycemic Agents, Insulin, Placenta, Pregnancy, Diabetes, Gestational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.